Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more
Daehan New Pharm Co. Ltd (054670) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.034x
Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has a cash flow conversion efficiency ratio of 0.034x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.43 Billion) by net assets (₩129.44 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daehan New Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Daehan New Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
-0.166x |
|
Borders & Southern Petroleum plc
PINK:BDRSF
|
-0.004x |
|
Mineros S.A.
PINK:MNSAF
|
0.101x |
|
Alchera Inc.
KQ:347860
|
-0.097x |
|
NICE Total Cash Management Co. Ltd
KQ:063570
|
0.146x |
|
Element 25 Ltd
AU:E25
|
-0.037x |
|
Kukdong Oil &
KO:014530
|
-0.021x |
|
PT Mulia Industrindo Tbk
JK:MLIA
|
0.004x |
Annual Cash Flow Conversion Efficiency for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daehan New Pharm Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩125.44 Billion | ₩18.95 Billion | 0.151x | +31.44% |
| 2023-12-31 | ₩109.36 Billion | ₩12.57 Billion | 0.115x | -16.99% |
| 2022-12-31 | ₩102.96 Billion | ₩14.25 Billion | 0.138x | -31.16% |
| 2021-12-31 | ₩82.47 Billion | ₩16.58 Billion | 0.201x | -15.19% |
| 2020-12-31 | ₩57.13 Billion | ₩13.55 Billion | 0.237x | -36.75% |
| 2019-12-31 | ₩61.07 Billion | ₩22.89 Billion | 0.375x | -21.12% |
| 2018-12-31 | ₩43.08 Billion | ₩20.47 Billion | 0.475x | +1113.94% |
| 2017-12-31 | ₩51.72 Billion | ₩-2.42 Billion | -0.047x | -138.14% |
| 2016-12-31 | ₩71.20 Billion | ₩8.75 Billion | 0.123x | +21.58% |
| 2015-12-31 | ₩77.20 Billion | ₩7.80 Billion | 0.101x | -25.43% |
| 2014-12-31 | ₩73.89 Billion | ₩10.02 Billion | 0.136x | -- |